Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report

A 49-year-old woman with ER-positive/PR-negative/HER2-negative metastatic breast cancer experienced Grade 3 hepatotoxicity following initiation of a clinical trial of fulvestrant, palbociclib, and erdafitinib. Fulvestrant was determined to be the drug most likely responsible for this hepatotoxic eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Schlotman, Alyssa, Stater, Adam, Schuler, Kyle, Heideman, Judd, Abramson, Vandana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154258/
https://www.ncbi.nlm.nih.gov/pubmed/32308596
http://dx.doi.org/10.1159/000506442
_version_ 1783521793385955328
author Schlotman, Alyssa
Stater, Adam
Schuler, Kyle
Heideman, Judd
Abramson, Vandana
author_facet Schlotman, Alyssa
Stater, Adam
Schuler, Kyle
Heideman, Judd
Abramson, Vandana
author_sort Schlotman, Alyssa
collection PubMed
description A 49-year-old woman with ER-positive/PR-negative/HER2-negative metastatic breast cancer experienced Grade 3 hepatotoxicity following initiation of a clinical trial of fulvestrant, palbociclib, and erdafitinib. Fulvestrant was determined to be the drug most likely responsible for this hepatotoxic effect. This case report details the timing and nature of this drug-induced liver injury, adding support to an area that has yet to be described adequately in the existing literature.
format Online
Article
Text
id pubmed-7154258
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-71542582020-04-19 Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report Schlotman, Alyssa Stater, Adam Schuler, Kyle Heideman, Judd Abramson, Vandana Case Rep Oncol Case Report A 49-year-old woman with ER-positive/PR-negative/HER2-negative metastatic breast cancer experienced Grade 3 hepatotoxicity following initiation of a clinical trial of fulvestrant, palbociclib, and erdafitinib. Fulvestrant was determined to be the drug most likely responsible for this hepatotoxic effect. This case report details the timing and nature of this drug-induced liver injury, adding support to an area that has yet to be described adequately in the existing literature. S. Karger AG 2020-03-24 /pmc/articles/PMC7154258/ /pubmed/32308596 http://dx.doi.org/10.1159/000506442 Text en Copyright © 2020 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Schlotman, Alyssa
Stater, Adam
Schuler, Kyle
Heideman, Judd
Abramson, Vandana
Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report
title Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report
title_full Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report
title_fullStr Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report
title_full_unstemmed Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report
title_short Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report
title_sort grade 3 hepatotoxicity following fulvestrant, palbociclib, and erdafitinib therapy in a patient with er-positive/pr-negative/her2-negative metastatic breast cancer: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154258/
https://www.ncbi.nlm.nih.gov/pubmed/32308596
http://dx.doi.org/10.1159/000506442
work_keys_str_mv AT schlotmanalyssa grade3hepatotoxicityfollowingfulvestrantpalbociclibanderdafitinibtherapyinapatientwitherpositiveprnegativeher2negativemetastaticbreastcanceracasereport
AT stateradam grade3hepatotoxicityfollowingfulvestrantpalbociclibanderdafitinibtherapyinapatientwitherpositiveprnegativeher2negativemetastaticbreastcanceracasereport
AT schulerkyle grade3hepatotoxicityfollowingfulvestrantpalbociclibanderdafitinibtherapyinapatientwitherpositiveprnegativeher2negativemetastaticbreastcanceracasereport
AT heidemanjudd grade3hepatotoxicityfollowingfulvestrantpalbociclibanderdafitinibtherapyinapatientwitherpositiveprnegativeher2negativemetastaticbreastcanceracasereport
AT abramsonvandana grade3hepatotoxicityfollowingfulvestrantpalbociclibanderdafitinibtherapyinapatientwitherpositiveprnegativeher2negativemetastaticbreastcanceracasereport

Ejemplares similares